The Ohio State University Comprehensive Cancer Center (OSUCCC) has five highly interactive cancer research programs. More than 200 scientists from 12 of the 14 colleges at The Ohio State University are members of one or more of these research programs. Most of the research in the Division of Surgical Oncology is translational, in which ideas and hypotheses from the laboratory are incorporated into clinical evaluation through the clinical trial mechanism.
Through the OSUCCC five programs, the work of members includes basic laboratory studies, translational research and clinical trials. While each program focuses on a different area of cancer research, the comprehensive cancer center promotes a strong culture of collaboration. Interprogrammatic collaborations, collaborations with researchers in these Ohio State colleges and collaborations with researchers at other cancer centers and institutions are encouraged. As a result, researchers can tackle complex and important questions that require broad, interdisciplinary expertise.
The research programs continue to grow in scientific and clinical strength through recruitment and retention of some of the world’s brightest minds in cancer research. The clear focus on collaborative and translational research and the availability of state-of-the-art technologies and expertise provided by 21 cores and shared resources, enables OSUCCC researchers to conduct high-quality research that leads to world-class discoveries, changes in clinical practice and improvements in patient care.
Surgical Oncology's Selected Research Grants
Carson III, William Edgar. Year 2 SWOG Network Group Operations Center of the NCTN. Oregon Health and Science University. $18,043. 03/01/15 – 02/29/16
Carson III, William Edgar. “Tumor Immunology.” Year 13 T32 Provides support to post-doctoral researchers performing translational research in immunology. NCI. $254,018. 08/01/2015-07/31/2016.
Farrar, William Blair. Breast and bowel treatment protocols agreement-SUBPART-B-50-I (KATHERINE) June 2013 Addendum. NSABP Fdn Inc. $56,065. 03/01/2013 - 02/28/2016
Farrar, William Blair. Breast and bowel treatment protocols agreement. NSABP Fdn Inc. $766,622. 02/01/1999 - 02/28/2016
Phay, John. Year 3: Core A: The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE (Phay). NCI. $258,500 08/01/2015 - 07/31/2016
Phay, John. Core A: Genetic and signaling pathways in epithelial thyroid cancer. NCI. $892,165. 04/30/2013 - 03/31/2016
Pollock, Raphael Etomar. Reactivating of apoptosis: A potential therapeutic target for desmoid tumors with CTNNB1 S45F mutation. Desmoid Tumor Research Foundation. $50,000. 12/01/2014 - 11/30/2015
Pollock, Raphael Etomar. Yr. 4 - SARC Sarcoma SPORE Core A. SARC.$19,905. 09/01/2015 - 08/31/2016
Pollock, Raphael Etomar. Yr. 4 - SARC Sarcoma SPORE Project 1. SARC. $19,025. 09/01/2015 - 08/31/2016
Yee, Lisa. Flaxseed lignan as a prevention strategy for pre-menopausal women at high risk for development of breast cancer. Univ of Kansas Center for Research, Inc. $25,000. 05/01/2013 - 09/23/2015
Yee, Lisa. Omega-3 fatty acids and ERPR(-) and HER-2/neu(+) breast cancer prevention. National Cancer Institute. $638,581. 01/13/2014 - 12/31/2015
To search for active research by program or researcher, please visit the OSUCCC official site at?: http://cancer.osu.edu/research-and-education
Clinical trials are research studies that involve people. They are the final step in a long process that begins with research in a lab, in some cases right here at Ohio State. Most treatments we use today are the result of past clinical trials.
Cancer clinical trials are designed to test new ways to:
• Treat cancer
• Find and diagnose cancer
• Prevent cancer
• Manage symptoms of cancer or side effects from its treatment
Any time you or a loved one needs treatment for cancer, clinical trials are an option to think about. Trials are available for all stages of cancer. It is a myth that they are only for people who have advanced cancer that is not responding to treatment.
Every trial has a person in charge, usually a doctor, who is called the principal investigator. The principal investigator prepares a plan for the trial, called a protocol. The protocol explains what will be done during the trial. It also contains information that helps the doctor decide if this treatment is right for you. The protocol includes information about:
• The reason for doing the trial
• Who can join the trial (called “eligibility requirements”)
• How many people are needed for the trial
• Any drugs that will be given, how they will be given, the dose, and how often
• What medical tests will be done and how often
• What types of information will be collected about the people taking part
Surgical Oncology’s Selected Clinical Trials
Agnese, Doreen. A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy. Alliance. Role: Local Principal Investigator. Status: Accruing.
Agnese, Doreen. The HEART Study: Heart Health in Breast Cancer Survivors. Role: Co-investigator
Agnese, Doreen. Prospective Cohort Study of BRCA1 & BRCA2 Carriers. Role: Principal Investigator. 2009
Agnese, Doreen. A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node (closed to accrual). Role: Local Principal Investigator. Sponsor: John Wayne Cancer Institute, NCI Status:
Carson III, William. Protocol: OSU-13023. Propranolol Hydrochloride in Treating Patients with Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery. A Pilot Study of Beta-Blockers in Patients with Advanced Cancer.
Carson III, William. Protocol: OSU-13024. A Phase IIb, Nonrandomized, Open-Label Trial with Mouse Renal Adenocarcinoma (RENCA) Cell-Containing Agarose-Agarose Macrobeads Compared with Best Supportive Care in Patients with Treatment-Resistant, Metastatic Colorectal Carcinoma
Farrar, William. NSABP B-50-I/OSU 10393. A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy.
Farrar, William. SWOG 1207. Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy. – actively accruing
Schmidt, Carl. Protocol: NCCTG-N1048. A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision.
Yee, Lisa. Protocol: OSU-13130. Omega-3 fatty acids and ERPR(-) and HER-2/neu(+) breast cancer prevention (Phase II Study).
Yee, Lisa. Protocol: OSU-13034. Nanoemulsion curcumin for obesity, inflammation and breast cancer prevention a pilot trial.
For a comprehensive list of all accruing clinical trials, please visit the OSUCCC Clinical Trails office site at: http://cancer.osu.edu/research-and-education/shared-resources/clinical-trials-office